Pharmacokinetic and pharmacodynamic study of intratumoral injection of an adenovirus encoding endostatin in patients with advanced tumors

Gene Therapy

Volumn 15, Issue 4, 2008, Pages 247-256

  Li, H L ^a,b   Li, S ^a   Shao, J Y ^a   Lin, X B ^a   Cao, Y ^a   Jiang, W Q ^a   Liu, R Y ^a   Zhao, P ^a   Zhu, X F ^a   Zeng, M S ^a   Guan, Z Z ^a   Huang, W ^a,c  

^a SUN YAT SEN UNIVERSITY   (China)

^b TIANJIN MEDICAL UNIVERSITY   (China)

^c INSTITUTE OF MICROBIOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ENDOSTATIN; ENDOSTATIN 10A; FIBROBLAST GROWTH FACTOR; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ADULT; ADVANCED CANCER; ARTICLE; BLOOD TOXICITY; CANCER GENE THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG TOLERABILITY; ENZYME IMMUNOASSAY; FEMALE; FEVER; HUMAN; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; LIVER TOXICITY; MALE; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SOLID TUMOR; TISSUE DISTRIBUTION; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; ADULT; ENDOSTATINS; FEMALE; GENETIC VECTORS; HALF-LIFE; HUMANS; INJECTIONS, INTRALESIONAL; MALE; MIDDLE AGED; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; TISSUE DISTRIBUTION;

ADENOVIRIDAE; ANIMALIA;

EID: 38949142281     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/sj.gt.3303038     Document Type: Article

References (29)

1. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003; 3: 401-410.:
2. Folkman J, Klagsbrun M. Angiogenic factors. Science 1987; 235 442-447.
3. Folkman J, Weisz PB, Joullie MM, Li WW, Ewing WR. Control of angiogenesis with synthetic heparin substitutes. Science 1989; 243: 1490-1493.
4. Zeng Q, Li S, Chepeha DB, Giordano TJ, Li J, Zhang H et al. Crosstalk between tumor and endothelial cells promotes tumor angiogenesis by MAPK activation of Notch signaling. Cancer Cell 2005; 8: 13-23.
5. Boehm T, Folkman J, Browder T, O'Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997; 390: 404-407.
6. Jain RK. Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 2005; 307: 58-62.
7. Folkman J. Antiangiogenesis in cancer therapy - endostatin and its mechanisms of action. Exp Cell Res 2006; 312: 594-607.
8. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W et al. Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal. cancer. N Engl J Med 2004; 350: 2335-2342.
9. Eggert A, Ikegaki N, Kwiatkowski J, Zhao H, Brodeur GM, Himelstein BP. High-level expression of angiogenic factors is associated with advanced mimor stage in human neuroblastomas. Clin Cancer Res 2600; 6 1900-1908.
10. Relf M, LeJeune S, Scott PA, Fox S, Smith K, Leek R et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 1997; 57: 963-969.
11. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS et al. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88: 277-285.
12. Dixelius J, Cross MJ, Matsumoto T, Claesson-Welsh L. Endostatin action'end intracellular signaling: Beta-catenin as a potential target? Cancer Lett 2003; 196: 1-12.
13. Abdollahi A, Hahnfeldt P, Maercker C,'Grone HJ, Debus J, Ansorge W et al. Endostatin's antiangiogenic signaling network Mol Cell 2004; 13: 649-663.
14. Li L, Liu RY, Huang JL, Liu QC, Li Y, Wu PH et al. Adenovirus-mediated intra-tumoral delivery of the human endostatin gene, inhibits tumor growth in nasopharyngeal carcinoma. Int J Cancer 2006; 118: 2064-2071.
15. Lang ZH, Wu PH, Li L, Xue G, Zeng YX, Huang WL. Inhibition of tumor growth in xenografted nude, mice with adenovirus-mediated 'endostatin gene, comparison with 'recombinant endostatin protein. Chin Med J (Engl) 2004; 117: 1809-1814.
16. Wu Y, Yang L, Hu, B, Liu, JY Su JM, Luo Y et al. Synergistic anti-tumor effect of recombinant human endostatin adenovirus combined-with gemcitabine. Anticancer Drugs 2005; 16: 551-557.
17. Sauter BV, Martinet O, Zhang WJ, Mandell J, Woo SL. Adenovirus-mediated gene transfer of endostatin in vivo results in high level of transgene expression and inhibition of tumor growth and metastases. Proc Natl Acad Sci USA 2000; 97; 4802-4807.
18. Capillo M, Mancuso P, Gobbi A, Monestiroli S, Pruneri G, Dell' Agnola'C et al. Continuous infusion of endostatin inhibits-differentiation, mobilization, and clonogenic, potential of endothelial cell progenitors. Clin Cancer Res 2003; 9: 377-382.
19. Kisker O, Becker CM, Prox D, Fannon M, D'Amato R, Flynn E et al. Continuous administration of endostatin by intraperitoneally implanted osmotic pump unproves the efficacy and potency of therapy in a mouse xenograft tumor model. Cancer Res 2001; 61: 7669-7674.
20. Herbst RS, Hess KR, Tran HT, Tseng JE, Mullani NA, Charnsangavej C et al. Phase I study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 2002; 20: 3792:-3803.
21. Eder Jr JP, Supko JG, Clark JW, Puchalski TA, Garcia-Carbonero R, Ryan DP et al. Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J Clin Oncol 2002; 20: 3772-3784.
22. Thomas JP, Arzoomanian RZ, Alberti D, Marnocha R, Lee F, Friedl A et al. Phase 1 pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 2003; 21: 223-231.
23. Skovseth DK, Veuger MJ, Sorensen DR, De Angelis PM, Haraldsen G. Endostatin dramatically inhibits endothelial cell migration, vascular morphogenesis, and perivascular cell recruitment in vivo. Blood 2005; 105: 1044-1051.
24. Hansma AH, Broxterman HJ, van der Horst I, Yuana Y, Boven E, Giaccone G et al. Recombinant human endostatin administered as a 28-day continuous intravenous infusion, followed by daily subcutaneous injections: A phase I and pharmaco-kinetic study in patients with advanced cancer. Ann Oncol 2005; 16: 4695-1701.
25. He GA, Xue G, Xiao L, Wu JX, Xu BL, Huang JL et al. Dynamic distribution and expression in vivo of human endostatin gene delivered by adenoviral vector. Life Sci 2005; 77: 1331-1340.
26. Abdollahi A, Hlatky L, Huber PE. Endostatin: The logic of antiangiogenic therapy. Drug Resist Updat 2005; 8: 59-74.
27. Hoekstra R, de Vos FY, Eskens FA, Gietema JA, van der Gaast A, Groen HJ et al. Phase I safety, pharmacokinetic, an pharmaco-dynamic study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced cancer. J Clin Oncol 2005; 23: 5188-5197.
28. Zhang YA, Nemunaitis J, Scanlon KJ, Tong AW. Anti-tumorigenic effect of a K-ras ribozyme against human lung cancer cell line heterotransplants' in nude. Gene Therapy 2000, 7: 2041-2050.
29. Slos P, De Meyer M, Leroy P, Rousseau C, Acres B. Immunotherapy of established tumors in mice by intratumoral injection of an adenovirus vector harboring the human IL-2, cDNA: Induction of CD8 (+) T-cell immunity and NK activity. Cancer Gene Ther 2001; 8: 321-332.